Method of administering decitabine

Details Method of administering decitabine Method of administering decitabine

2006-11-14

2006-11-14

Lewis, Patrick T. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S042000, C514S043000

Reexamination Certificate

active

07135464

ABSTRACT:
Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.

REFERENCES:
patent: 3817980 (1974-06-01), Vorbruggen et al.
patent: 4022889 (1977-05-01), Bannister et al.
patent: 4477442 (1984-10-01), Skulnick et al.
patent: 4684630 (1987-08-01), Repta et al.
patent: 4690918 (1987-09-01), Beppu et al.
patent: 4910021 (1990-03-01), Davis et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5700640 (1997-12-01), Voss et al.
patent: 5736531 (1998-04-01), Von Borstel et al.
patent: 5856090 (1999-01-01), Epstein
patent: 5856094 (1999-01-01), Sidransky et al.
patent: 5968914 (1999-10-01), Von Borstel et al.
patent: 6136791 (2000-10-01), Nyce
patent: 6225325 (2001-05-01), Jacob
patent: 6255293 (2001-07-01), Kimchi
patent: 6309666 (2001-10-01), Hatano et al.
patent: 6613753 (2003-09-01), Rubinfeld et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 2001/0012835 (2001-08-01), Fine et al.
patent: 2002/0114809 (2002-08-01), Rubinfeld et al.
patent: 2002/0136709 (2002-09-01), Zahner
patent: 2003/0013099 (2003-01-01), Lasek et al.
patent: 2003/0039689 (2003-02-01), Chen et al.
patent: 2003/0045497 (2003-03-01), Widegren et al.
patent: 2003/0108588 (2003-06-01), Chen et al.
patent: 2003/0147813 (2003-08-01), Lyons
patent: 2003/0165864 (2003-09-01), Lasek et al.
patent: 2003/0171303 (2003-09-01), Gallop et al.
patent: 2003/0229047 (2003-12-01), Joshi-Hangal et al.
patent: 269077 (1963-12-01), None
patent: 1922702 (1969-05-01), None
patent: 2105468 (1971-02-01), None
patent: 286958 (1988-04-01), None
patent: 05219974 (1992-02-01), None
patent: 2002223753 (2001-01-01), None
patent: 2002370939 (2001-06-01), None
patent: 2003310293 (2002-04-01), None
patent: WO 93/01202 (1991-07-01), None
patent: WO 94/26761 (1993-05-01), None
patent: WO 94/27632 (1993-06-01), None
patent: WO 96/11280 (1994-10-01), None
patent: WO 96/36693 (1995-05-01), None
patent: WO 96/39035 (1995-06-01), None
patent: WO 96/40165 (1995-06-01), None
patent: WO 98/14619 (1996-10-01), None
patent: WO 98/16186 (1996-10-01), None
patent: WO 98/29108 (1996-12-01), None
patent: WO 98/54318 (1997-05-01), None
patent: WO 00/05419 (1998-07-01), None
patent: WO 00/23112 (1998-10-01), None
patent: WO 00/40269 (1999-01-01), None
patent: WO 00/54574 (1999-03-01), None
patent: WO 00/62075 (1999-04-01), None
patent: WO 01/21215 (1999-09-01), None
patent: WO 01/69262 (2000-03-01), None
patent: WO 01/79164 (2000-03-01), None
patent: WO 02/18592 (2000-09-01), None
patent: WO 02/21140 (2000-09-01), None
patent: WO 02/051980 (2000-12-01), None
patent: WO 02/057425 (2001-01-01), None
patent: WO 02/076486 (2001-02-01), None
patent: WO 02/083705 (2001-04-01), None
patent: WO 02/085400 (2001-04-01), None
patent: WO 02/087586 (2001-04-01), None
patent: WO 03/006950 (2001-07-01), None
patent: WO 03/011209 (2001-07-01), None
patent: WO 03/012085 (2001-07-01), None
patent: WO 03/012112 (2001-07-01), None
patent: WO 03/026574 (2001-09-01), None
patent: WO 03/031932 (2001-10-01), None
patent: WO 03/040363 (2001-11-01), None
patent: WO 03/043631 (2001-11-01), None
patent: WO 03/045427 (2001-11-01), None
patent: WO 03/046190 (2001-11-01), None
patent: WO 03/065995 (2002-02-01), None
patent: WO 03/076593 (2002-03-01), None
patent: WO 03/076594 (2002-03-01), None
patent: WO 03/086374 (2002-04-01), None
patent: WO 2003/087774 (2002-04-01), None
patent: WO 03/104427 (2002-06-01), None
patent: WO 2004/009023 (2002-07-01), None
patent: WO 02/069903 (2002-09-01), None
patent: PCT/US04/22367 (2005-07-01), None
Lin et al. Journal of Pharmaceutical Sciences (1981), vol. 70 (11), pp. 1228-1232.
Von Hoff, et al., “5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia,”Annals of Internal Medicine(1976) 85(2), pp. 237-245.
Sheikhnejad, G. et al., “Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine”,J. Mol. Biol.,1999, pp. 2021-2034, vol. 285.
Goffin, J. et al., “DNA methyltransferase inhibitors—state of the art”,Annals of Oncology,2002, pp. 1699-1716, vol. 13.
Wijermans, P. et al., “Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients”,Journal of Clinical Oncology,Mar. 2000, pp. 956-962, vol. 18, No. 5.
Brown, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy.Expert Rev Anticancer Ther.2004; 4(4): 501-510.
Gilbert, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation.Clinical Cancer Research.2004; 10: 4589-4596.
Herman, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation.The New England Journal of Medicine.2003; 349(21): 2042-2054.
Leone, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.Haematologica.2002; 87(12): 1324-1341.
Leone, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.Clin Immunol.2003; 109(1): 89-102.

Affiliated with

Also associated with

Rating

Method of administering decitabine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of administering decitabine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of administering decitabine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3652342